Cyclacel Pharmaceuti (CYCCP)

$7.30 +0.26 (3.69%)
Market Cap N/A
Revenue (ttm) 420,000.00
Net Income (ttm) -22.56M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 300
Avg Vol 3,386
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 40%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

Industry: Biotechnology
Sector: Healthcare
Phone: 60 9 08517 7330
Address:
Level 10, Tower 11 Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
schaeffers
schaeffers Jul. 18 at 12:44 PM
Monday's Ex-Dividend Stocks: 💊 $CYCCP: $0.15 on 8/1 💼 $OCCI: $0.115 on 7/31 💼 $OCCIM: $0.1640625 on 7/31 💼 $OCCIN: $0.109375 on 7/31 💼 $OCCIO: $0.1276042 on 7/31 🦴 $RDUS: $0.1875 on 8/4 🚀 $SSSS: $0.25 on 7/31
0 · Reply
HaltTradeAlert
HaltTradeAlert Jul. 15 at 2:54 PM
$CYCCP Halt Time: 10:51:54 Issue Symbol: CYCCP Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
Aburose
Aburose Jul. 15 at 2:35 PM
$CYCCP It will explode in a moment, we may see 30-40
0 · Reply
Aburose
Aburose Jul. 15 at 2:24 PM
$CYCCP any time it will move
0 · Reply
Aburose
Aburose Jul. 15 at 2:13 PM
$CYCCP soon
0 · Reply
topstockalerts
topstockalerts Jul. 15 at 12:50 PM
Pre Market Top Gainers PT2 $SXTP $MOVE $KC $IBG $CYCCP
0 · Reply
topstockalerts
topstockalerts Jul. 15 at 11:25 AM
Pre Market Top Gainers PT2 $SXTP $MOVE $KC $IBG $CYCCP
0 · Reply
BioTuesdays
BioTuesdays Jul. 7 at 3:21 PM
Cyclacel Pharmaceuticals has announced the publication of independent research in the peer-reviewed medical journal Gut demonstrating that plogosertib, a PLK1 inhibitor, is active in fibrolamellar hepatocellular carcinoma (FLC)—a rare and hard-to-treat subtype of liver cancer $CYCC $CYCCP https://biotuesdays.com/2025/07/07/cyclacel-highlights-publication-in-gut-showing-plogosertib-is-active-in-flc/
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 10 at 2:06 PM
$CYCCP Halt Time: 10:04:01 Issue Symbol: CYCCP Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
CHeePY_10ORBitZ
CHeePY_10ORBitZ Jun. 3 at 12:52 PM
$CYCCP Market missing what USAU is sitting on
0 · Reply
Latest News on CYCCP
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

Jul 15, 2025, 12:17 PM EDT - 13 days ago

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

CYCC

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

Jul 7, 2025, 6:00 AM EDT - 21 days ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

CYCC

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Jul 7, 2025, 6:00 AM EDT - 21 days ago

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

CYCC

Cyclacel Pharmaceuticals Announces Stock Split

Jul 2, 2025, 9:00 AM EDT - 26 days ago

Cyclacel Pharmaceuticals Announces Stock Split

CYCC

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Jun 20, 2025, 4:30 PM EDT - 5 weeks ago

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCC

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Jun 3, 2025, 4:15 PM EDT - 7 weeks ago

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CYCC

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 15, 2025, 12:50 AM EDT - 2 months ago

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCC

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

May 7, 2025, 9:00 AM EDT - 2 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCC

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

May 6, 2025, 6:00 AM EDT - 2 months ago

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

CYCC

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Apr 2, 2025, 4:05 PM EDT - 4 months ago

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

CYCC

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Mar 24, 2025, 7:30 AM EDT - 4 months ago

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

CYCC

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Feb 27, 2025, 1:38 PM EST - 5 months ago

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

CYCC

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Jan 3, 2025, 9:01 AM EST - 7 months ago

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

CYCC

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Dec 5, 2024, 4:05 PM EST - 8 months ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

CYCC

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 14, 2024, 4:15 PM EST - 9 months ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

CYCC

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 13, 2024, 12:22 PM EST - 9 months ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

CYCC

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Nov 12, 2024, 4:45 PM EST - 9 months ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CYCC

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Oct 24, 2024, 9:15 AM EDT - 9 months ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

CYCC

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 23, 2024, 9:15 AM EDT - 9 months ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCC

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 9:15 AM EDT - 10 months ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCC

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Sep 25, 2024, 9:15 AM EDT - 10 months ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

CYCC

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:15 AM EDT - 11 months ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

CYCC

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Sep 3, 2024, 9:15 AM EDT - 11 months ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

CYCC

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:18 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

CYCC

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Aug 7, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

CYCC

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Jun 26, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

CYCC

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

CYCC

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:08 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

CYCC

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

May 8, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

CYCC

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

May 2, 2024, 4:30 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

CYCC

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CYCC

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Apr 1, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

CYCC

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 6:09 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

CYCC

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CYCC

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

CYCC

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 7, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

CYCC

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Mar 6, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

CYCC

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Feb 20, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

CYCC

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Jan 30, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

CYCC

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jan 8, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

CYCC

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Jan 2, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

CYCC

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Dec 22, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

CYCC

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Dec 18, 2023, 9:00 AM EST - 1 year ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

CYCC

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Dec 12, 2023, 4:05 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

CYCC

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Nov 30, 2023, 9:15 AM EST - 1 year ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

CYCC

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Nov 28, 2023, 5:15 PM EST - 1 year ago

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

CYCC

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:32 PM EST - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

CYCC

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

Nov 7, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

CYCC

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

Aug 3, 2023, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

CYCC

Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript

May 11, 2023, 7:59 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript

CYCC

schaeffers
schaeffers Jul. 18 at 12:44 PM
Monday's Ex-Dividend Stocks: 💊 $CYCCP: $0.15 on 8/1 💼 $OCCI: $0.115 on 7/31 💼 $OCCIM: $0.1640625 on 7/31 💼 $OCCIN: $0.109375 on 7/31 💼 $OCCIO: $0.1276042 on 7/31 🦴 $RDUS: $0.1875 on 8/4 🚀 $SSSS: $0.25 on 7/31
0 · Reply
HaltTradeAlert
HaltTradeAlert Jul. 15 at 2:54 PM
$CYCCP Halt Time: 10:51:54 Issue Symbol: CYCCP Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
Aburose
Aburose Jul. 15 at 2:35 PM
$CYCCP It will explode in a moment, we may see 30-40
0 · Reply
Aburose
Aburose Jul. 15 at 2:24 PM
$CYCCP any time it will move
0 · Reply
Aburose
Aburose Jul. 15 at 2:13 PM
$CYCCP soon
0 · Reply
topstockalerts
topstockalerts Jul. 15 at 12:50 PM
Pre Market Top Gainers PT2 $SXTP $MOVE $KC $IBG $CYCCP
0 · Reply
topstockalerts
topstockalerts Jul. 15 at 11:25 AM
Pre Market Top Gainers PT2 $SXTP $MOVE $KC $IBG $CYCCP
0 · Reply
BioTuesdays
BioTuesdays Jul. 7 at 3:21 PM
Cyclacel Pharmaceuticals has announced the publication of independent research in the peer-reviewed medical journal Gut demonstrating that plogosertib, a PLK1 inhibitor, is active in fibrolamellar hepatocellular carcinoma (FLC)—a rare and hard-to-treat subtype of liver cancer $CYCC $CYCCP https://biotuesdays.com/2025/07/07/cyclacel-highlights-publication-in-gut-showing-plogosertib-is-active-in-flc/
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 10 at 2:06 PM
$CYCCP Halt Time: 10:04:01 Issue Symbol: CYCCP Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
CHeePY_10ORBitZ
CHeePY_10ORBitZ Jun. 3 at 12:52 PM
$CYCCP Market missing what USAU is sitting on
0 · Reply
KamenKirev
KamenKirev May. 27 at 3:15 PM
$CYCCP gave me 16% yield 10 days ago
0 · Reply
halted_stocks
halted_stocks May. 9 at 11:51 PM
$CYCCP CYCCP halted @ 4,05 - 19:50:00 - T1 Halt - News Pending Price: 4,05 | Change: -0,12 (-2,88%) HOD: 4,05 | LOD: 4,05 | MC: 131,31M Volume: 103 | SMA50: 5,51 | SMA200: 7,08 Shares Outstanding: 32,25M
0 · Reply
Wisenheimer
Wisenheimer Apr. 8 at 7:57 PM
$CYCCP $CYCC theses are last in line look at new classes of shares and preferences - and they havent even done the major dilution yet - good luck getting anything out of them in china
0 · Reply
wacomarine
wacomarine Apr. 8 at 6:46 PM
$CYCC well $CYCCP is the prefered stock to $CYCC and its running... so i just picked myself up 5000 shares and we'll see where she goes tomorrow
0 · Reply
patb99
patb99 Apr. 8 at 6:39 PM
$CYCCP 4$ ☺️
0 · Reply
wacomarine
wacomarine Apr. 8 at 6:39 PM
$CYCC does $CYCCP have anything to do with this stock?
1 · Reply
HaltTradeAlert
HaltTradeAlert Apr. 8 at 6:37 PM
$CYCCP Halt Time: 14:35:22 Issue Symbol: CYCCP Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
patb99
patb99 Apr. 8 at 6:33 PM
$CYCCP 🧐
0 · Reply
HaltTradeAlert
HaltTradeAlert Apr. 8 at 6:25 PM
$CYCCP Halt Time: 14:24:23 Issue Symbol: CYCCP Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
HaltTradeAlert
HaltTradeAlert Apr. 8 at 6:14 PM
$CYCCP Halt Time: 14:13:32 Issue Symbol: CYCCP Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 29 at 12:37 PM
$CYCCP Biotech's got potential here. Fadraciclib looks promising in early trials. Clinical data coming Q4 could be a catalyst. Small position might make sense for risk-tolerant investors. Management cutting costs, exploring strategic options. Watching closely for next moves. compelling article: https://beyondspx.com/article/cyclacel-pharmaceuticals-inc-cycc-a-resilient-biotech-navigating-challenges-and-pursuing-promising-cancer-therapies
0 · Reply
HaltTradeAlert
HaltTradeAlert Mar. 4 at 7:39 PM
$CYCCP Halt Time: 14:38:39 Issue Symbol: CYCCP Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply